scispace - formally typeset
D

David Fiorella

Researcher at Stony Brook University

Publications -  349
Citations -  20708

David Fiorella is an academic researcher from Stony Brook University. The author has contributed to research in topics: Aneurysm & Stroke. The author has an hindex of 67, co-authored 328 publications receiving 17960 citations. Previous affiliations of David Fiorella include Emory University & State University of New York System.

Papers
More filters
Journal ArticleDOI

A dedicated cerebrovascular anesthesia team is a critical component of a comprehensive stroke center.

TL;DR: As thrombectomy has become established as the standard of care for emergent large vessel occlusion (ELVO), it is time that neurointerventional surgery evolves in the same direction as have other subspecialties such as cardiothoracic surgery, which typically have a dedicated, specialized, anesthesia team.
Journal ArticleDOI

The interaction of clozapine with the meta-chlorophenylpiperazine (mCPP) discriminative stimulus.

TL;DR: The present data indicate that the paradigm of mCPP-induced stimulus control does not facilitate the differentiation of atypical and typical antipsychotic activities.
Journal ArticleDOI

Safety of the APOLLO Onyx delivery microcatheter for embolization of brain arteriovenous malformations: Results from a prospective post-market study

TL;DR: The Apollo Onyx delivery microcatheter (Apollo) is a single lumen catheter designed for controlled delivery of Onyx into the neurovasculature, with a detachable distal tip to aid catheter retrieval.
Journal ArticleDOI

Immediate flow-diversion characteristics of a novel primarily bioresorbable flow-diverting stent.

TL;DR: The bioresorbable stent has immediate flow-diversion characteristics that are comparable to commercially available metal stents, and longer-term studies are underway to determine the ability of the resorbable fibers to act as a neointimal scaffold and result in long-term aneurysm occlusion.
Journal ArticleDOI

CREST: equipoise realized

TL;DR: Findings in safety were largely determined by important differences in the rate of perioperative stroke and myocardial infarction, and the notion that MI was weighted equal to stroke as a major adverse event (MAE) in a trial examining treatment arms designed to prevent only stroke might be questioned.